Always up to date.
 

Our goal is to develop procedure and anatomy specific devices that lead in collaboration with our customers to predictable and superior treatment outcomes. Read on to learn more about our solutions, priorities, partnerships and how we create sustainable value with our teams.

Medartis has decided not to pursue the convertible bond placement

Ad hoc announcement pursuant to Art. 53 LR

Basel, 8 April 2022: The Board of Medartis has decided not to pursue the planned convertible bond placement, which was announced on Thursday evening. The...

Read more

Medartis launches senior convertible bond offering with a target size of CHF 125-150 million

Ad hoc announcement pursuant to Art. 53 LR

Basel, 7 April 2022: Medartis Holding AG (SIX: MED, the “Issuer” or “Medartis”), a specialized orthopaedic company for head and extremity surgery, announces...

Read more

Medartis shareholders approve all proposals of the Board of Directors

    Ad hoc announcement pursuant to Art. 53 LR
  • 84.8% of the total share capital was represented at this year's Annual General Meeting
  • All proposals of the Board of Directors were approved with a...
Read more